ALMS — ALUMIS INC (Healthcare >> Biotechnology)
ALMS FAQ
What is ALMS's P/E ratio?
ALUMIS INC (ALMS) currently trades at a P/E ratio of 43.01.
What is ALMS's ROE?
ALUMIS INC reports a Return on Equity (ROE) of -41.87%.
What is ALMS's dividend yield?
ALUMIS INC offers a dividend yield of 0.00%.
What is ALMS's Deepscope Quality Score?
Deepscope rates ALMS's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ALMS?
Deepscope's AI Timing Score for ALMS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ALMS belong to?
ALUMIS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 20.06
Price
0.05
(0.25%)
Day Change
|
|
|---|
ALMS Chất lượng tổng thể của cố phiếu Không tốt ( Chất lượng = 31) và Thời điểm mua ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
[-] Tốc độ tăng trưởng ROE dưới mức tiêu chí của chúng tôi.
Lịch sử ROE tương đối thấp
ROA quá thấp so với ROE
Tốc độ tăng trưởng ROA dưới mức tiêu chí của chúng tôi.
Biên lợi nhuận ròng tương đối thấp.
Tốc độ tăng trưởng biên lợi nhuận ròng dưới mức tiêu chí của chúng tôi
Lịch sử Biên lợi nhuận ròng tương đối thấp.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Không tốt lắm , ...
| Yếu tố Chất lượng |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 20.06 |
| PBV / Sector |
4.50 / 4.79
|
| Earning Per Share | -1.87 |
| PE / Sector |
43.01 / 17.89
|
| PEG or PE/Growth / Sector |
1.84 / 0.56
|
| Average 1M Daily Value |
21.11 M
GREAT
|
| Average 1W Daily Value |
24.50 M
GREAT
|
| Yếu tố Kỹ thuật |
|
28% |
| Sức khỏe tài chính |
|
45% |
| Khả năng kiếm lợi nhuận |
|
52% |
| Lợi tức cho nhà đầu tư |
|
8% |
| Chi tiết đăng ký |
| Analyze Date | 2026-06-11 09:55:04 |
| Symbol | ALMS |
| Name | ALUMIS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 123.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,551.11 / 8,963.32 |
| Tin tức, Dự báo ước tính |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 280 East Grand Avenue, South San Francisco, CA, United States, 94080
Phone: 650 231 6625
Website: https://www.alumis.com
Employees: 225
Sector: Healthcare >> Biotechnology
Description: Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google